Cheng Qing, Lu Li, Grafström Jonas, Olofsson Maria Hägg, Thorell Jan-Olov, Samén Erik, Johansson Katarina, Ahlzén Hanna-Stina, Linder Stig, Arnér Elias S J, Stone-Elander Sharon
Division of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
Biochim Biophys Acta. 2013 Mar;1830(3):2562-73. doi: 10.1016/j.bbagen.2012.12.007.
Radiolabeled annexin A5 (AnxA5) is widely used for detecting phosphatidylserine exposed on cell surfaces during apoptosis. We describe here a new method for labeling AnxA5 and a size-matched control protein with short-lived carbon-11, for probing the specificity of in vivo cell death monitoring using positron emission tomography (PET) imaging.
AnxA5 and the control protein were recombinantly expressed with a C-terminal "Sel-tag", the tetrapeptide -Gly-Cys-Sec-Gly-COOH. The proteins were then labeled either fluorescently for in vitro corroborations of binding behaviors or with 11C for dynamic in vivo PET studies.
AnxA5 demonstrated retained calcium-dependent binding to apoptotic cells after the C-terminus modification. The control protein showed no functional binding. The 11C-ligands demonstrated similar in vivo pharmacokinetic behavior in healthy mice except for higher uptake in kidney and higher intact elimination to urine of AnxA5. After inducing hepatic apoptosis, however, the uptake of labeled AnxA5 in the targeted tissue increased compared to baseline levels while that of the control protein tended to decrease.
These data suggest that the combined use of these two tracers can facilitate differentiating specific AnxA5 binding and its changes caused by induced cell death from uptake due to non-specific permeability and retention effects at baseline or after therapy.
The Sel-tag enables rapid and mild reactions with electrophilic agents giving site-specifically labeled proteins for multi-probe analyses. The combined use of 11C-labeled AnxA5 and a size-matched control protein with dynamic PET can be useful for evaluating drug effects on target as well as off-target tissues.
放射性标记的膜联蛋白A5(AnxA5)广泛用于检测细胞凋亡过程中暴露于细胞表面的磷脂酰丝氨酸。我们在此描述一种用短寿命碳-11标记AnxA5和大小匹配的对照蛋白的新方法,用于使用正电子发射断层扫描(PET)成像探究体内细胞死亡监测的特异性。
AnxA5和对照蛋白通过C末端的“Sel标签”(四肽-Gly-Cys-Sec-Gly-COOH)进行重组表达。然后对蛋白质进行荧光标记以用于体外结合行为的验证,或用11C进行动态体内PET研究。
C末端修饰后,AnxA5表现出对凋亡细胞的钙依赖性结合保留。对照蛋白未显示出功能性结合。除了在肾脏中的摄取较高以及AnxA5向尿液中的完整清除率较高外,11C配体在健康小鼠中表现出相似的体内药代动力学行为。然而,诱导肝细胞凋亡后,与基线水平相比,靶向组织中标记的AnxA5摄取增加,而对照蛋白的摄取则趋于减少。
这些数据表明,这两种示踪剂的联合使用有助于区分特异性AnxA5结合及其由诱导的细胞死亡引起的变化与基线或治疗后由于非特异性通透性和保留效应导致的摄取。
Sel标签能够与亲电试剂发生快速且温和的反应,产生位点特异性标记的蛋白质用于多探针分析。11C标记的AnxA5和大小匹配的对照蛋白与动态PET联合使用可用于评估药物对靶组织和非靶组织的作用。